Search Medical Condition
Please enter condition
Please choose location

Congestive Heart Failure Clinical Trials

A listing of Congestive Heart Failure medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (181) clinical trials

A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction

The objective of the study is to find the optimal dose of once daily oral neladenoson bialanate (BAY1067197) when given in addition to appropriate therapy for specific comorbidities.


Continued Access Protocol for the Evaluation of the OPTIMIZER Smart System

The Continued Access study is a prospective, non-randomized, multi-center study designed to allow controlled access to the Optimizer Smart System until the PMA order has been issued by the FDA.

Phase N/A

Point of Care Precision and Sample Comparison Study of Minicare BNP at Innsbruck Hospital - MI-BNP-CE04-AN2016

Study Design Part 1 (POC precision) Two levels of BNP control samples (Thermofisher) will be tested during 5 days, with 5 replicates per day by three different users to assess precision of the Minicare BNP. The two different levels need to be tested on the same analyzer by the same ...

Phase N/A

Study to Assess the Safety Tolerability and PK Response and Explore the PD Response Following 4 Weekly SC Injections of PB1046 in Subjects With Stable Heart Failure With Reduced Ejection Fraction (HFrEF)

Qualifying subjects will have a diagnosis of NYHA Class II or III heart failure with a reduced ejection fraction (HFrEF), be in stable condition, and be taking clinician-directed appropriate pharmacological therapy (e.g., angiotensin converting enzyme inhibitors, angiotensin receptor blockers or an evidence based beta blocker) for heart failure at stable ...


RecoverLINK Technology Pilot for HF Patients

The primary objective is to examine feasibility of incorporating RecoverLINK into the standard of care as a function of (i) user engagement, (ii) user satisfaction, and (iii) workflow efficiency. As secondary objectives, the investigators will collect preliminary data to examine the association between patient engagement with the RecoverLINK app and ...

Phase N/A

Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)

- Purpose of the study The primary hypothesis of the PRIME-HF study is that, compared with usual care, a treatment strategy of initiation of ivabradine prior to discharge for a hospitalization for acute HF will be associated with a greater proportion of participants using ivabradine at 180 days. Secondary objectives ...


Study on the Effect of Influenza Vaccination After Heart Attack on Future Cardiovascular Prognosis

Name of investigational treatment: Influenza vaccine (Vaxigrip, Sanofi Pasteur MSD). Title of study: Influenza vaccination After Myocardial Infarction (IAMI trial). Study centers: Up to 35 centers in Sweden, Denmark, Norway, Scotland, Czech Rebublic and Latvia. Planned study period: 2016 - 2019 from October 1 to March 1 (influenza season). Long-term ...


Protected PCI Study

The objective of the study is to assess the safety and efficacy of the IMPELLA® 2.5 System in subjects undergoing non-emergent high-risk percutaneous coronary intervention (PCI) post market approval. The primary endpoint will be a composite clinical endpoint of major adverse events through 90 days following the PCI procedure. The ...

Phase N/A

MultiPoint Pacing Post Market Study

Any patient who received a market approved SJM Quadra Allure MP, Quadra Assura MP, or newer SJM CRT MP device is eligible for enrollment in the study. MultiPoint Pacing (MPP) programming guidance will be specified in the protocol. Patients will be followed for 12 months after implant. Data will be ...


Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy

This is a post-market clinical study of HM II patient management practices to be conducted in the United States. Subjects will be randomized in a 1:1 fashion to the following research drug groups: 1. Treatment Arm: Warfarin (INR target: 2.0-2.5, median: 2.25) + Placebo (1 pill/day) 2. Control Arm: Warfarin ...

Phase N/A